More Prescient Therapeutics Limited news
Prescient Therapeutics LimitedASX: PTX

Canadian Patent Granted for PTX-200

May 15, 2019 at 11:46 PM EDT · Issued by Prescient Therapeutics Limited

Filed with ASX · May 15, 2019 at 11:46 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/canadian-patent-granted-for-ptx-200

Prescient Therapeutics Limited on 6ix

Story so far

  • US Patent Granted for PTX-200 for Ovarian Cancer TreatmentJul 26, 2018
  • European Patent Granted for PTX-200May 12, 2017

Earlier from Prescient Therapeutics

  • Entitlement Offer Results and Shortfall NotificationApr 26, 2019
  • March 2019 Appendix 4C - QuarterlyApr 24, 2019
  • Despatch of Entitlement Offer DocumentsApr 3, 2019
  • ProspectusMar 24, 2019
  • Capital Raising Presentation - March 2019Mar 24, 2019

Later from Prescient Therapeutics

  • Change to Exercise Price of OptionsMay 30, 2019
  • PTX Initiates Phase 1b Clinical Trial for PTX-100Jul 10, 2019
  • June 2019 Appendix 4C - QuarterlyJul 23, 2019
  • Appendix 4E and 2019 Annual ReportAug 25, 2019
  • September 2019 Appendix 4C - QuarterlyOct 29, 2019
All Prescient Therapeutics news releases↗

Follow Prescient Therapeutics into a list and get an email when it puts out news.

Follow Prescient Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer